Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28925355 | 0.88 | MPO (0.40) | MPO | |
| SCHEMBL22231861 | 0.86 | MPO (0.50) | MPOSLC6A2SLC6A4SLC6A3DAO | |
| SCHEMBL22232441 | 0.84 | MPO (0.35) | MPOGAAALDH1A1ESR1ESR2 | |
| SCHEMBL22232129 | 0.83 | MPO (0.41) | MPOGAAALDH1A1PTGS1PTGS2 | |
| SCHEMBL29454245 | 0.82 | MEN1 (0.44) | MPOSLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL22232191 | 0.82 | MEN1 (0.44) | MPOSLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL22231812 | 0.82 | NR3C2 (0.38) | MPOSLC6A4PTPN7DUSP3 | |
| SCHEMBL22232363 | 0.81 | RET (0.40) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL22232006 | 0.81 | CYP3A4 (0.40) | MPOSLC6A2SLC6A4SLC6A3GAA | |
| SCHEMBL29454343 | 0.81 | CYP3A4 (0.40) | MPOSLC6A2SLC6A4SLC6A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | claimed |
| EP-4647426-A2 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2025-11-12 | — | — | EP | claimed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | claimed |
| EP-3911629-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2021-11-24 | — | — | EP | claimed |
| WO-2020148617-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2020-07-23 | — | — | WO | claimed |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | disclosed |
| EP-4647426-A2 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2025-11-12 | — | — | EP | disclosed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | disclosed |
| EP-3911629-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2021-11-24 | — | — | EP | disclosed |
| CN-113454063-A | 3-substituted phenylamidine compounds, preparation method and application thereof | PI工业有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020148617-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | H1-3, PRMT7, PFAS | MPO 1451/4885SLC6A2 2448/4885SLC6A4 1815/4885 |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | CBR1, CBR3, HCCS | MPO 2443/4885SLC6A2 1636/4885SLC6A4 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.